share_log

Atea Pharmaceuticals Analyst Ratings

Benzinga ·  Aug 10, 2023 17:28
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
08/10/2023 JP Morgan Downgrades Neutral → Underweight
03/16/2023 125.99% JP Morgan $12 → $8 Maintains Neutral
01/27/2023 69.49% SVB Leerink $8 → $6 Maintains Market Perform
01/24/2023 12.99% Morgan Stanley $7 → $4 Maintains Underweight
08/15/2022 97.74% Morgan Stanley $6 → $7 Maintains Underweight
03/02/2022 125.99% JP Morgan $10 → $8 Maintains Neutral
03/01/2022 154.24% SVB Leerink $10 → $9 Maintains Market Perform
02/16/2022 182.49% SVB Leerink $11 → $10 Maintains Market Perform
01/06/2022 97.74% Morgan Stanley $14 → $7 Downgrades Equal-Weight → Underweight
11/18/2021 210.73% SVB Leerink → $11 Downgrades Outperform → Market Perform
10/20/2021 464.97% SVB Leerink $60 → $20 Maintains Outperform
10/20/2021 351.98% JP Morgan $61 → $16 Downgrades Overweight → Neutral
10/05/2021 1453.67% Morgan Stanley → $55 Downgrades Overweight → Equal-Weight
09/09/2021 1594.92% SVB Leerink → $60 Initiates Coverage On → Outperform
08/18/2021 945.2% Morgan Stanley $35 → $37 Maintains Overweight
06/03/2021 888.7% Morgan Stanley $82 → $35 Maintains Overweight
04/06/2021 2216.38% Morgan Stanley $49 → $82 Maintains Overweight
01/29/2021 1764.41% JP Morgan $45 → $66 Maintains Overweight
11/25/2020 Evercore ISI Group Initiates Coverage On → Outperform
11/24/2020 1171.19% JP Morgan → $45 Initiates Coverage On → Overweight
11/24/2020 William Blair Initiates Coverage On → Outperform
11/24/2020 1284.18% Morgan Stanley → $49 Initiates Coverage On → Overweight

What is the target price for Atea Pharmaceuticals (AVIR)?

The latest price target for Atea Pharmaceuticals (NASDAQ: AVIR) was reported by JP Morgan on August 10, 2023. The analyst firm set a price target for $0.00 expecting AVIR to fall to within 12 months (a possible -100.00% downside). 5 analyst firms have reported ratings in the last year.

What is the most recent analyst rating for Atea Pharmaceuticals (AVIR)?

The latest analyst rating for Atea Pharmaceuticals (NASDAQ: AVIR) was provided by JP Morgan, and Atea Pharmaceuticals downgraded their underweight rating.

When is the next analyst rating going to be posted or updated for Atea Pharmaceuticals (AVIR)?

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Atea Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Atea Pharmaceuticals was filed on August 10, 2023 so you should expect the next rating to be made available sometime around August 10, 2024.

Is the Analyst Rating Atea Pharmaceuticals (AVIR) correct?

While ratings are subjective and will change, the latest Atea Pharmaceuticals (AVIR) rating was a downgraded with a price target of $0.00 to $0.00. The current price Atea Pharmaceuticals (AVIR) is trading at is $3.54, which is out of the analyst's predicted range.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment